0.2905
2.19%
-0.0065
Qualigen Therapeutics Inc stock is currently priced at $0.2905, with a 24-hour trading volume of 9,216.
It has seen a -2.19% decreased in the last 24 hours and a -27.56% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.3043 pivot point. If it approaches the $0.2897 support level, significant changes may occur.
Previous Close:
$0.297
Open:
$0.3
24h Volume:
9,216
Market Cap:
$1.83M
Revenue:
$4.79M
Net Income/Loss:
$-13.42M
P/E Ratio:
-0.0723
EPS:
-4.02
Net Cash Flow:
$-10.30M
1W Performance:
-8.65%
1M Performance:
-27.56%
6M Performance:
-60.59%
1Y Performance:
-67.63%
Qualigen Therapeutics Inc Stock (QLGN) Company Profile
Name
Qualigen Therapeutics Inc
Sector
Industry
Phone
760 918 9165
Address
2042 Corte Del Nogal, Carlsbad
Qualigen Therapeutics Inc Stock (QLGN) Latest News
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
GlobeNewswire Inc.
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
GlobeNewswire Inc.
Why Richardson Electronics Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket
Benzinga
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
GlobeNewswire Inc.
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
GlobeNewswire Inc.
Qualigen Therapeutics Inc Stock (QLGN) Financials Data
Qualigen Therapeutics Inc (QLGN) Revenue 2024
QLGN reported a revenue (TTM) of $4.79 million for the quarter ending June 30, 2022, a +0.62% rise year-over-year.
Qualigen Therapeutics Inc (QLGN) Net Income 2024
QLGN net income (TTM) was -$13.42 million for the quarter ending December 31, 2023, a +28.02% increase year-over-year.
Qualigen Therapeutics Inc (QLGN) Cash Flow 2024
QLGN recorded a free cash flow (TTM) of -$10.30 million for the quarter ending December 31, 2023, a +22.22% increase year-over-year.
Qualigen Therapeutics Inc (QLGN) Earnings per Share 2024
QLGN earnings per share (TTM) was -$2.66 for the quarter ending December 31, 2023, a +45.38% growth year-over-year.
About Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Cap:
|
Volume (24h):